UUTINEN > Korona 11.04.2020 > 92 PROSENTILLA 1061:STA ERINOMAINEN LOPPUTULOS > Hydroksiklorokiinilla ja asitromysiinillä hoidettiin 1061 potilasta Ranskassa

UUTINEN > Korona 11.04.2020 > 92 PROSENTILLA 1061:STA ERINOMAINEN LOPPUTULOS > Hydroksiklorokiinilla ja asitromysiinillä hoidettiin 1061 potilasta Ranskassa.

04/2020: Dr. Oz: "Dr. Didier Raoult met with French President Emmanuel Macron yesterday, and the infectious disease expert sent me an update following their meeting."
Aiempaa tietoa Dr. Didier Raoultin hoitotuloksista: Dr. Didier Raoult > Wikipedia > On 17 March 2020, Raoult announced that a trial involving 36 patients from the south east of France supported the claim that Hydroxychloroquine and Azithromycin were effective in treating for COVID-19
https://en.wikipedia.org/w/index.php?title=Didier_Raoult&oldid=950091973


Lisätietoa 11.04.2020

"ninety two percent of the patients therefore had excellent outcomes, because they weren't in the hospital for more than ten days and they didn't have a persistent virus for more than ten days"

4 % of the patience had a persistente virus past ten days

Kommentti: Jos potilas on jo lähellä tehohoito-/hengityskonevaihetta, niin oletettavasti elimistö on lääkinnällisestikin paljon vaikeampi saada terveeksi...eli lääkitys pitää aloittaa mahdollisimman aikaisin koronavirustartunnan saamisesta, jopa ennen kuin koronavirustaudista on tietoakaan (?). Tehohoito-/hengityskonevaiheessa potilas alkaa olla niin finaalissa, että siinä ei välttämättä enää mikään auta pelastamaan henkeä.

Dr. Didier Raoult: "defines a poor outcome being in hospital for more than ten days"

Ohessa videon automaattisesti luotua litteraattia, jossa voi olla monenlaisia kirjoitusvirheitä, mutta siitä saa parhaimmillaan olennaisen selville erittäin selkeästi:

00:00

everybody breaking news I just got a

00:02

note from the dear old he met with the

00:05

French premier McCrone yesterday and

00:07

presented data from his most recent

00:09

update and he sent me the abstract of

00:11

that paper just an hour or so ago it was

00:14

a thousand sixty one patients they were

00:17

treated early with hydroxychloroquine 

00:19

that's the malaria drug we've talked

00:21

about with azithromycin the

00:23

z-pak and I'm gonna go through the data

00:25

so you all understand it four percent of

00:27

the patients had a persistent virus past

00:29

ten days

00:30

that means ninety six percent of the

00:31

patients were not infectious after that

00:33

initial period he thinks that's

00:35

important because it reduces the ability

00:37

of the virus to spread four percent of

00:39

these thousand sixty one patients he

00:41

says had a poor outcome but he defines a

00:43

poor outcome as being in the hospital

00:45

for more than ten days right and that's

00:47

actually the pretty strict criteria but

00:51

he had ten people go to the ICU and he (ICU = Intensive Care Unit = Tehohoito)

00:53

had five deaths out of the thousand

00:55

sixty-one patients again there's no

00:57

control study there's no group that was

00:59

designed to compare this to but he says

01:01

compared to the patients who weren't on

01:02

this medication and compared to results

01:04

in other parts of France those are

01:06

superior results we'll have to look at

01:07

the final analysis to assess that ninety

01:10

two percent of the patients therefore

01:13

had excellent outcomes in his mind

01:15

because they weren't in the hospital for

01:16

more than ten days and they didn't have

01:19

a persistent virus for more than ten

01:20

days now couple observations are

01:22

important first off he found him to be

01:24

very safe with low side effects that

01:26

reflects earlier information but also as

01:28

he's argued and others has made the

01:29

point as well as been used these

01:31

medications in the hundreds of millions

01:33

of people maybe billions of people

01:35

without major concerns so it reinforces

01:37

that with appropriate doctorate

01:39

prescriptions it should be safely

01:41

administer secondly he noticed that the

01:43

percent the amount of the

01:45

hydroxychloroquine in your blood

01:47

correlated with outcomes and that's

01:49

important because we hadn't thought

01:50

about the fact that people might absorb

01:51

it differently and that's a critical

01:53

issue and then finally he looked at the

01:56

potentially increased risk of some

01:58

medications and particular blood

01:59

pressure medications which were

02:00

correlated with worse outcomes and the

02:03

one that caught my attention was the

02:04

angiotensin ii receptor blockers these

02:06

are commonly used blood pressure

02:08

medications he's arguing that these are

02:10

a problem because

02:12

the group of patients who had those

02:14

medications 30% of them had persistent

02:16

virus that's three times more than the

02:18

regular group and 30% of them had a poor

02:20

outcome which is you know seven or eight

02:22

times more than the average participant

02:24

in the trial I also want to point out

02:26

that's the same receptor that the virus

02:27

uses to get into our body so there's a

02:29

theoretical reason why there's a concern

02:31

for that it should prompt more

02:32

investigation there's a new NIH trial

02:34

that's about to start 500 patient trial

02:36

these are the kinds of endpoints that

02:37

should be studying as well to give us

02:39

more clarity on these insights again

02:41

more information to help educate doctors

02:43

and make that doctor-patient discussion

02:45

a bit more robust I hope you found this

02:47

helpful be sure to subscribe to my

02:49

channel so you don't miss anything and

02:51

remember to check back often to see

02:53      what's new


LISÄTIETOA
https://hauskat-videot.blogspot.com/search/label/Hydroksiklorokiini